Welcome to our dedicated page for Alterity Therapeutics news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics stock.
Alterity Therapeutics Limited develops treatments for neurodegenerative diseases, with a clinical program centered on Multiple System Atrophy and related Parkinsonian disorders. News about ATHE commonly covers ATH434, its lead MSA candidate, Phase 2 analyses, FDA interactions, chemistry, manufacturing and control updates, and presentations at neurology and imaging conferences.
Coverage also includes bioMUSE Natural History Study biomarker work, including quantitative susceptibility mapping MRI for iron dysregulation in MSA, Appendix 4C cash flow and corporate updates, board appointments, and discussions of the company’s drug discovery platform for patentable chemical compounds targeting neurological disease pathology.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has secured an exclusive license from UniQuest to develop novel zinc ionophore technology aimed at fighting antimicrobial resistance to superbugs. This technology, which utilizes Alterity's PBT2, allows for the re-sensitization of bacteria to antibiotics, addressing a critical health issue. PBT2 has shown potential in reversing antibiotic resistance in preclinical studies and is patented until 2038. The partnership with UniQuest may significantly enhance Alterity's commercial prospects while maintaining focus on its primary program for ATH434.
Alterity Therapeutics (ATHE) announced the allowance of a new patent by the USPTO, covering over 150 novel compounds aimed at treating neurodegenerative diseases such as Parkinson's and Alzheimer's. This patent grants 20 years of exclusivity, bolstering the company's drug development portfolio. Alterity's lead candidate, ATH434, shows promise in clinical development, demonstrating favorable safety and efficacy in animal models. CEO Geoffrey Kempler emphasized the significance of this patent in pursuing innovative therapeutic options for serious brain diseases.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced the start of patient enrollment for its bioMUSE Study focusing on Multiple System Atrophy (MSA) on Oct. 26, 2020. The study, conducted in collaboration with Vanderbilt University Medical Center, aims to track disease progression in early-stage MSA patients. The bioMUSE study data will inform the upcoming Phase 2 clinical trial of Alterity's lead compound, ATH434, which has completed Phase 1 trials. MSA is a debilitating neurodegenerative condition with no approved therapies, making this study crucial for advancing treatment options.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced new clinical data for its drug candidate ATH434, which will be presented at the 2020 International Congress of Parkinson's Disease and Movement Disorders and the American Neurological Association's Annual Meeting. New animal data confirms ATH434's effectiveness in reducing α-synuclein pathology and preserving neurons in a Multiple System Atrophy model. Additionally, new safety data indicates ATH434 has no significant cardiac liability, supporting its advancement to Phase 2 development after FDA discussions.
Alterity Therapeutics Limited (NASDAQ: ATHE) announced positive developments regarding its lead compound ATH434, receiving FDA guidance for its clinical development, including agreement on the Phase 2 study design. The company reported a cash balance of $9.2M, bolstered by an additional $1.5M from a recent share issuance. Furthermore, Alterity has resolved its previous compliance issue with NASDAQ regarding the minimum bid price requirement, confirming re-compliance.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced a successful pre-IND meeting with the FDA regarding its lead compound, ATH434, for treating Multiple System Atrophy (MSA). Following a Phase 1 clinical trial, the FDA provided guidance on the Phase 2 study design, including safety monitoring and patient population. Importantly, there are no approved treatments for MSA, prompting collaboration with the FDA to establish appropriate efficacy endpoints. The company will also conduct a natural history study called bioMUSE to better track disease progression.